OCT 04, 2021 8:29 PM PDT

Guillain-Barre Syndrome After COVID-19 Infection

WRITTEN BY: Alexandria Bass

Researchers with the International GBS Outcome Study (IGOS) consortium investigated newly-diagnosed GBS patients from the beginning of the pandemic – January to March 2020 – to determine if there was an increased incidence of GBS related to SARS-CoV-2 infection. GBS cases have spiked in the past to the 1976 H1N1 swine flu vaccination and to the 2015 Zika virus pandemic.

Guillain-Barre is an autoimmune disease where progressive muscle weakness occurs as a result of immune destruction of nerves in the peripheral nervous system. There are different variants of GBS, with acute inflammatory demyelinating polyradiculoneuropathy (AIDP) being the most common form in the US. The AIDP variant involves sensory changes and symmetrical, rapidly progressive limb weakness that usually starts in the legs and moves upward, potentially paralyzing respiratory muscles. Other symptoms include numbness, tingling, and autonomic dysfunction that can cause cardiac arrhythmias and unstable blood pressures. 

Onset can occur after surgeries, medications, and gut and respiratory infections, such as infection with Campylobacter jejuni, Mycoplasma pneumoniae, Haemophilus influenzae, cytomegalovirus, and Epstein-Barr virus. Symptoms usually present around 3 weeks after infection and become most severe by 4 weeks from symptom onset. 

GBS is diagnosed through antibody testing for ganglioside antibodies, lumbar puncture for cerebrospinal examination, and electromyography and nerve conduction studies. Characteristic CSF findings include high protein levels with normal white blood cell counts.

Neurological conditions have been linked to COVID-19 infection. Other than the typical loss of sense of smell and taste, more serious neurological symptoms are strokes, changes in consciousness, and injury to the skeletal muscles. SARS-CoV-2 is thought to cause neurological symptoms by attaching to the ACE2 receptor present on nerve and muscle tissues.

In this international prospective observational cohort study, IGOS researchers did not detect an increase in GBS diagnosis during the first 4 months of the COVID-19 pandemic, suggesting GBS is not very likely to develop after COVID-19 infection. 

Of the 49 patients examined in the study, 8 had a confirmed and 3 had a probable COVID-19 infection before developing GBS symptoms, with no evidence of having had another recent infection that could explain the onset of GBS. COVID-19-related GBS cases were associated with a sensorimotor, demyelinating variant and with severe symptoms of GBS.
 

About the Author
  • Alexandria (Alex) is a freelance science writer with a passion for educating the public on health issues. Her other professional experience includes working as a speech-language pathologist in health care, a research assistant in a food science laboratory, and an English teaching assistant in Spain. In her spare time, Alex enjoys cycling, lap swimming, jogging, and reading.
You May Also Like
NOV 08, 2021
Technology
Violent Video Games Can Make Players More Aggressive, Just Not Towards Other People
NOV 08, 2021
Violent Video Games Can Make Players More Aggressive, Just Not Towards Other People
Do violent video games cause players to initiate real-life acts of aggression and violence? The question is one that&rsq ...
NOV 15, 2021
Drug Discovery & Development
Injectable Therapy Reverses Paralysis within 4 Weeks
NOV 15, 2021
Injectable Therapy Reverses Paralysis within 4 Weeks
Researchers have developed an injectable therapy that can repair tissue damage and reverse paralysis in mice within four ...
NOV 18, 2021
Immunology
Could Maternal Antibodies Contribute to Autism Development?
NOV 18, 2021
Could Maternal Antibodies Contribute to Autism Development?
Pregnant mothers pass on oxygen and nutrients to their developing babies while shuttling away waste products from the fe ...
NOV 22, 2021
Health & Medicine
Important Considerations in the Humanization of Antibodies
NOV 22, 2021
Important Considerations in the Humanization of Antibodies
In therapeutic applications, monoclonal antibodies (mAbs) provide highly precise targeting of pathological cells and red ...
NOV 17, 2021
Drug Discovery & Development
FDA greenlights clinical trials for novel COVID-19 vaccine and delivery system
NOV 17, 2021
FDA greenlights clinical trials for novel COVID-19 vaccine and delivery system
Last week the United States Food and Drug Administration (FDA) authorized the biotechnology company Inovio to ...
NOV 18, 2021
Cannabis Sciences
Is Cannabis Useful for Symptoms of Endometriosis?
NOV 18, 2021
Is Cannabis Useful for Symptoms of Endometriosis?
Endometriosis is a common gynecologic disorder impacting up to 10% of women of reproductive age in the United ...
Loading Comments...